| 08/10 | HC Wainwright Lowers BioNTech SE's Price Target to $272 From $283, Maintains Buy Rating | MT |
| 08/09 | European ADRs Move Higher in Tuesday Trading | MT |
| 08/09 | Drugmaker Gilead to help fund monkeypox education for LGBTQ+ groups | RE |
| 08/09 | Goldman Sachs Cuts BioNTech SE's Price Target to $200 From $209, Keeps Neutral Rating | MT |
| 08/09 | INSIDER SELL : Regeneron Pharmaceuticals | MT |
| 08/09 | INSIDER SELL : Regeneron Pharmaceuticals | MT |
| 08/09 | BIONTECH : Berenberg reiterates its Buy rating | MD |
| 08/09 | BIONTECH : Buy rating from Berenberg | MD |
| 08/09 | Berenberg Bank Adjusts BioNTech's Price Target to $312 From $350, Maintains Buy Rating | MT |
| 08/09 | BIONTECH : Goldman Sachs remains Neutral | MD |
| 08/09 | EU Health Agency Starts Real-time Review of Pfizer-BioNTech's Variant-specific COVID-19.. | MT |
| 08/08 | SECTOR UPDATE : Health Care Stocks Getting Late Boost Back to Positive Ground | MT |
| 08/08 | SECTOR UPDATE : Health Care Stocks Edging Lower This Afternoon | MT |
| 08/08 | SECTOR UPDATE : Health Care | MT |
| 08/08 | BioNTech Q2 Profit, Revenue Decline; Shares Drop | MT |
| 08/08 | Morgan Stanley Raises Vertex Pharmaceuticals' Price Target to $253 From $250, Maintains.. | MT |
| 08/08 | UBS Adjusts Vertex Pharmaceuticals Price Target to $335 From $327, Maintains Buy Rating | MT |
| 08/08 | European ADRs Move Higher in Monday Trading | MT |
| 08/08 | TRENDING : BioNTech Expects Demand Increase in 4Q Despite Lower Earnings | DJ |
| 08/08 | SECTOR UPDATE : Health Care Stocks Edge Higher Early Monday | MT |
| 08/08 | BioNTech ADRs Fall 10% On Lower 2Q Revenue | DJ |
| 08/08 | BioNTech Seeks Acquisitions | CI |
| 08/08 | TRANSCRIPT : BioNTech SE, Q2 2022 Earnings Call, Aug 08, 2022 | CI |
| 08/08 | Equities Signal Stronger Session in US as More Earnings Eyed; Asia Mixed, Europe Higher | MT |
| 08/08 | Wall Street Leans Forward Pre-Bell; Futures Green, Europe Up, Asia Uneven | MT |
| 08/08 | BioNTech Flags Possible October Distribution of Omicron-targeted Vaccine; Shares Down 6.. | MT |
| 08/08 | BioNTech Logs H1 Profit Growth Following COVID-19 Vaccine Leadership | MT |
| 08/08 | BioNTech SE Reports Earnings Results for the Second Quarter and Six Months Ended June 3.. | CI |
| 08/08 | BioNTech Reiterates Revenue Guidance for the Full Year 2022 | CI |
| 08/08 | ANALYST RECOMMENDATIONS : Cigna, Duke Energy, Vertex Pharmaceuticals, EOG Resources, Motor.. | |
| 08/08 | BioNTech Reports Lower 2Q Earnings, But Sees Demand Uptick in 4Q | DJ |
| 08/05 | Goldman Sachs Adjusts Price Target for Vertex Pharmaceuticals to $389 From $368, Mainta.. | MT |
| 08/05 | HC Wainwright Raises Vertex Pharmaceuticals Price Target to $300 From $275, Maintains B.. | MT |
| 08/05 | BioNTech, Genmab Expand Cancer Treatment Collaboration to Address Malignant Solid Tumor.. | MT |
| 08/05 | Barclays Adjusts Price Target on Vertex Pharmaceuticals to $307 From $291, Reiterates O.. | MT |
| 08/05 | RBC Raises Price Target on Vertex Pharmaceuticals to $278 From $269, Maintains Sector P.. | MT |
| 08/05 | Genmab, BioNTech Expand Cancer Therapy Collaboration | MT |
| 08/05 | Genmab, BioNTech Expand Research Partnership for Cancer Treatments | DJ |
| 08/04 | TRANSCRIPT : Vertex Pharmaceuticals Incorporated, Q2 2022 Earnings Call, Aug 04, 2022 | CI |
| 08/04 | Vertex Pharmaceuticals Reports Higher Q2 Adjusted Profit, Revenue; Lifts 2022 Product R.. | MT |
| 08/04 | Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORATED Reports Q2 EPS $3.60 | MT |
| 08/04 | Vertex Pharmaceuticals Incorporated Reports Earnings Results for the Second Quarter and.. | CI |
| 08/04 | Vertex Pharmaceuticals Incorporated Reports Unaudited Intangible Asset Impairment Charg.. | CI |
| 08/04 | EARNINGS REACTION HISTORY : Vertex Pharmaceuticals, 50.0% Follow-Through Indicator, 2.4% S.. | MT |
| 08/04 | Goldman Sachs Increases Regeneron Pharmaceuticals' Price Target to $796 From $790, Main.. | MT |
| 08/04 | UBS Adjusts Gilead Sciences Price Target to $65 From $63, Maintains Neutral Rating | MT |
| 08/04 | Morgan Stanley Raises Regeneron Pharmaceuticals' Price Target to $625 From $619, Mainta.. | MT |
| 08/04 | Gilead Sciences to Buy UK Biotech Firm MiroBio for $405 Million | MT |
| 08/04 | RBC Raises Price Target on Regeneron Pharmaceuticals to $647 From $640, Maintains Secto.. | MT |
| 08/04 | Gilead Sciences, Inc. entered into a definitive agreement to acquire MiroBio Ltd from S.. | CI |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
